Asset profile
RTA 402
Small molecule
Evidence outlook · registrational
Type 2 Diabetes: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT00811889: The study randomized 227 participants to placebo or one of three RTA 402 doses and used quadruple blinding, with change in eGFR as the primary efficacy endpoint. However, no results are posted, so whether the primary endpoint was met cannot be determined.
The BEAM primary endpoint was met as shown, but the successor phase 3 (BEACON) was terminated for heart-failure safety events and the clinical meaning of bardoxolone's eGFR increase remains contested.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.